金陵药业(000919.SZ)：噁拉戈利片获批开展Ⅲ期临床研究

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) has received approval from the National Medical Products Administration for the clinical trial of Orelizumab tablets, marking a significant step in its development pipeline [1] Group 1: Company Developments - Jinling Pharmaceutical's subsidiary, Nanjing Jinling Pharmaceutical Factory, has been granted a clinical trial application acceptance notice for Orelizumab tablets [1] - The company has also received the Drug Clinical Trial Approval Notice, allowing the commencement of Phase III clinical research for Orelizumab tablets [1] Group 2: Product Information - Orelizumab is an oral GnRH antagonist primarily used for treating moderate to severe pain associated with endometriosis [1] - The product is included in the National "Second Batch of Encouraged Generic Drug List" [1]